Published on 9 Nov 2023 on Zacks via Yahoo Finance
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
Fate Therapeutics FATE reported a loss of 46 cents per share in the third quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 59 cents and the year-ago loss of 86 cents.
The loss narrowed year over year due to lower research and development (R&D) expenses.
The company earned collaboration revenues of $2 million in the third quarter, which also surpassed the Zacks Consensus Estimate of $1 million but was down from $15 million reported in the year-ago quarter.